Search bioRxiv⌕ Search

Biology subjects

Khanna, M.

Publications and source records attributed to Khanna, M..

6 recordsLinked to original sources

Identifying interactions between TDP-43 N-terminal and RNA binding domains

TAR DNA-binding Protein 43 (TDP-43) plays a crucial role in the pathophysiology and progression of Amyotrophic Lateral Sclerosis (ALS), affecting both familial and sporadic cases. TDP-43 is an intrinsically disordered multidomain protein that consists of an N-terminal domain (NTD1-102), two tandem RNA recognition motifs (RRM1102-177 and RRM2191-260), and an intrinsically disordered glycine-rich C-terminal261-414 domain. We previously identified a chemical probe which led to allosteric alterations between the RRM and NTD of TDP-43. We attributed these changes to potential interdomain interactions between the NTD and RRM segments. In this work, we compared the 2D [1H,15N] HSQC-NMR resonances of two constructs, TDP-43102-260 (RRM domain alone) against TDP-431-260 (NTD linked to RRM) and observed clustered shifts in the RNA binding sites of both RRM domains. To investigate why these shifts appeared in the RRM domains, in the absence of RNA, we hypothesized that the NTD domain could be stacking on the RRM domains. Thus, we modeled NTD-RRM interactions using protein-protein docking along with de novo sequence-to-structure predictions of TDP-431-260 that propose NTD stacking onto the RRM domains. Using Carr-Purcell-Meiboom-Gill (CPMG)-relaxation dispersion NMR spectroscopy, we demonstrated evidence of an interaction between NTD1-102 and RRMs102-260. Finally, we investigated the impact of NTD on RNA binding using 2D 15N-HSQC-NMR and microscale thermophoresis (MST) by titration of a short UG-rich RNA sequence and observed significant changes in RNA binding between TDP-43102-260 and TDP-431-260, further suggesting the NTD plays a role in TDP-43 RNA interactions.

biophysics↗

Immunoinformatic approach to design CTL epitope based chimeric vaccine targeting multiple serotypes of dengue virus

The dengue outbreak is one of the serious global public health concerns. The World Health Organization reported 3,80,171 cases and 113 deaths this year till March 2023, and the rate of infection is expected to increase in vulnerable parts of the world. The development of vaccines is the best approach to managing infectious diseases. All the approved vaccines against dengue are based on live-attenuated virus but they have been questioned for their effectiveness in some population categories. Additionally, random occurrence of four closely related serotypes of dengue virus in humans leading to antibody-dependent enhancement of the disease is yet another cause of vaccine ineffectiveness. Therefore, development of a therapeutic subunit-vaccine based on epitopes from all four serotypes may be expected to provide effective cross-protective cellular immunity. Towards this end, we designed a multi-epitope chimeric immunogen using envelop protein of dengue virus. The MHC-I binding T-cell epitopes were predicted based on their immunogenicity, allergenicity and antigenicity. NetMHCpan-EL4.1 prediction method was used to determine the binding ability of the epitopes with HLA alleles with population coverage of over 99%. The five most potent epitopes based on their immunogenicity, population coverage and prediction scores were selected for each serotype and a multi-epitope polypeptide was generated by merging peptides with AAY linker. The polypeptide was predicted to be an antigen and a non-allergen with a stable tertiary structure retaining a half-life of 4.4 hours in mammalian system. The polypeptide has the potential to elicit effective cellular immune response against all the dengue virus serotypes.

bioinformatics↗

Neuropilin-1 is a co-receptor for NGF and TrkA-evoked pain

Nerve growth factor (NGF) monoclonal antibodies inhibit chronic pain yet, failed to gain approval due to worsened joint damage in osteoarthritis patients. We report that neuropilin-1 (NRP1) is a co-receptor for NGF and tropomyosin-related kinase A (TrkA) pain signaling. NRP1 is coexpressed with TrkA in human and mouse nociceptors. NRP1 inhibitors suppress NGF-stimulated excitation of human and mouse nociceptors and NGF-evoked nociception in mice. NRP1 knockdown inhibits NGF/TrkA signaling, whereas NRP1 overexpression enhances signaling. NGF binds NRP1 with high affinity and interacts with and chaperones TrkA from the biosynthetic pathway to the plasma membrane and endosomes, enhancing TrkA signaling. Molecular modeling suggests that C-terminal R/KXXR/K NGF motif interacts with extracellular "b" NRP1 domain within a plasma membrane NGF/TrkA/NRP1 of 2:2:2 stoichiometry. G Alpha Interacting Protein C-terminus 1 (GIPC1) scaffolds NRP1 and TrkA to myosin VI and colocalizes in nociceptors with NRP1/TrkA. GIPC1 knockdown abrogates NGF-evoked excitation of nociceptors and pain-like behavior. NRP1 is a nociceptor-enriched co-receptor that facilitates NGF/TrkA pain signaling. NRP binds NGF and chaperones TrkA to the plasma membrane and signaling endosomes via the GIPC1 adaptor. NRP1 and GIPC1 antagonism in nociceptors offers a long-awaited non-opioid alternative to systemic antibody NGF sequestration for the treatment of chronic pain. SummaryNeuropilin-1 and G Alpha Interacting Protein C-terminus 1 are necessary for nerve growth factor-evoked pain and are non-opioid therapeutic targets for chronic pain.

neuroscience↗

Identification and targeting of a unique NaV1.7 domain driving chronic pain

Despite identification of several small molecules directly targeting the voltage-gated sodium channel NaV1.7, none has been clinically successful. We reported that preventing addition of a small ubiquitin-like modifier (SUMO) on the NaV1.7-interacting cytosolic collapsin response mediator protein 2 (CRMP2) blocked NaV1.7 functions and was antinociceptive in rodents. Here, we discovered a 15 amino acid CRMP2 regulatory sequence (CRS) unique to NaV1.7 that is essential for this regulatory coupling. CRMP2 preferentially bound to the NaV1.7 CRS over other isoforms. Substitution of the NaV1.7 CRS with the homologous domains from the other eight voltage-gated sodium channel isoforms decreased tetrodotoxin-sensitive NaV1.7 currents in rodent sensory neurons. A cell-penetrant version of NaV1.7-CRS reduced NaV1.7 currents and trafficking, decreased presynaptic NaV1.7 localization, reduced spinal neurotransmitter release, and reversed mechanical allodynia in a rat spared nerve injury model of neuropathic pain. Interfering with NaV1.7-CRMP2 coupling did not produce motor impairment and spared thermal, inflammatory, and post-surgical nociception. As proof-of-concept for NaV1.7-targeted gene therapy, we found that NaV1.7-CRS packaged into an adeno-associated virus recapitulated the effects on NaV1.7 function in both rodent and rhesus macaque sensory neurons and both reversed and prevented the development of mechanical allodynia in a neuropathic pain model in male and female rodents. One Sentence SummaryA novel regulatory domain on the voltage gated sodium channel NaV1.7 that can be targeted to produce analgesia.

neuroscience↗

Molecular Dynamics simulation of TDP-43 RRM in the presence and absence of RNA

Structural characterization of the prion prone TAR DNA Binding protein (TDP)-43 has been challenging since its intrinsically disordered regions represents 15-30% of the total protein. TDP-43 is a nucleic acid binding protein with an N-terminal domain, two RNA Recognition Motifs (RRM1 and RRM2) and the C-terminal domain. In this study, we seek to define possible new targetable sites on the apo structure of TDP-43 RRM domains. To do so, we used molecular dynamic (MD) simulations on the NMR solved TDP-43RRM1-2 structure bound to RNA to predict the apo structure. Contact analysis of TDP-43 showed that while the integrity of the individual domains was maintained upon RNA removal, a decrease in interdomain contacts was observed. Moreover, we compared apo TDP-43 structures obtained from MD to AlphaFold 2 (AF2) predicted TDP-43 structures and found differences in loop regions. A Sitemap analysis identified five druggable sites for the RNA bound structure solved by NMR, while fewer sites were identified following MD simulations and AF2 predicted apo structures.

biophysics↗

Targeting the CaV - interaction yields a selective antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy

Inhibition of voltage-gated calcium (CaV) channels is a potential therapy for many neurological diseases including chronic pain. Neuronal CaV1/CaV2 channels are composed of , {beta} and 2{delta} subunits. The {beta}-subunits of CaV channels are cytoplasmic proteins that increase the surface expression of the pore-forming subunit of CaV. We targeted the high-affinity protein-protein interface of CaV{beta}s pocket within the CaV-subunit. Structure-based virtual screening of 50,000 small molecule library docked to the {beta}-subunit led to the identification of 2-(3,5-dimethylisoxazol-4-yl)-N-((4-((3-phenylpropyl)amino)quinazolin-2-yl)methyl)acetamide (compound 45). This small molecule bound to CaV{beta} and inhibited its coupling with N-type voltage-gated calcium (CaV2.2) channels, leading to a reduction in CaV2.2 currents in rat dorsal root ganglion (DRG) sensory neurons, decreased pre-synaptic localization of CaV2.2 in vivo, decreased frequency of spontaneous excitatory post-synaptic potentials (sEPSC), and inhibited release of the nociceptive neurotransmitter calcitonin gene related peptide (CGRP) from spinal cord. 45 was antinociceptive in naive animals and reversed allodynia and hyperalgesia in models of acute (post-surgical) and neuropathic (spinal nerve ligation, chemotherapy- and gp120-induced peripheral neuropathy, and genome-edited neuropathy) pain. 45 did not cause akinesia or motor impairment, a common adverse effect of CaV2.2 targeting drugs, when injected into the brain. 45, a quinazoline analog, represents a novel class of CaV2.2-targeting compounds that may serve as probes to interrogate CaV-{beta} function and ultimately be developed as a non-opioid therapeutic for chronic pain.

neuroscience↗